Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
| somatic mutation
|  
|  
|  
|
in pancreas and endometrial carcinomas, in Barrett's adenocarcinoma (and esophageal squamous cell carcinoma), in hepatocellular carcinoma with poor prognosis and in Merckel cell carcinoma |
tumoral
|  
| LOH
|  
|  
|
in both APC and TP53 in colorectal tumors and TP53 only in hepatocellular carcinoma |
tumoral
|  
|  
|  
| loss of function
|
in breast, adrenal, brain tumors |
tumoral
| somatic mutation
|  
|  
|  
|
in basal cell carcinoma (BCC) of the skin |
tumoral
|  
|  
|  
| loss of function
|
biallelic inactivation of derived from two distinct events, the germinative Arg337His mutation and the acquired loss of the entire chromosome 17, in adrenocortical tumor |
tumoral
| fusion
|  
|  
|  
|
TP53/FXR2 fusion protein lacks the ability of wild-type TP53 to function as a transcription factor; TP53/FXR2 gene is the first reported TP53 fusion gene in acute megakaryoblastic leukemia cell ![](pubmed.jpg) |
tumoral
|  
|  
|  
| loss of function
|
leading to depletion of mtDNA in breast cancer ![](pubmed.jpg) |
tumoral
|  
|  
| --over
|  
|
of KIT, TP53, and MKI67 reflects tumor grade and predicts survival in neuroendocrine carcinomas, but fail as prognostic markers in the subset of small cell lung cancer patients ![](pubmed.jpg) |
tumoral
| germinal mutation
|  
|  
| loss of function
|
in patients with primary ovarian, fallopian tube, or peritoneal cancers ![](pubmed.jpg) |